

( (S (NP-SBJ-1 (NP Earnings)
	       (PP for
		   (NP (NP most)
		       (PP of
			   (NP (NP the nation 's)
			       major pharmaceutical makers)))))
     (VP are
         (VP believed
             (S (NP-SBJ *-1)
                (VP to
                    (VP have
                        (VP moved
                            (ADVP-DIR ahead)
                            (ADVP-MNR briskly)
                            (PP-TMP in
				    (NP the third quarter))
			    ,
			    (SBAR-ADV as
				      (S (NP-SBJ (NP companies)
						 (PP with
						     (NP newer , big-selling prescription drugs)))
					 (VP fared
					     (ADVP-MNR especially well))))))))))
     .))
( (S (PP For
         (NP the third consecutive quarter))
     ,
     (ADVP however)
     ,
     (NP-SBJ-1 (NP most)
	       (PP of
		   (NP (NP the companies ')
		       revenues)))
     (VP were
         (VP battered
             (NP *-1)
             (PP by
                 (NP-LGS adverse foreign-currency translations))
             (PP-PRP as
		     (NP (NP a result)
			 (PP of
			     (NP (NP the strong dollar)
				 (ADVP-LOC abroad)))))))
     .))
( (S (NP-SBJ Analysts)
     (VP said
         (SBAR that
               (S (NP-SBJ (NP Merck & Co.)
			  ,
			  (NP Eli Lilly & Co.)
			  ,
			  (NP Warner-Lambert Co.)
			  and
			  (NP (NP the Squibb Corp. unit)
			      (PP of
				  (NP Bristol-Myers Squibb Co.))))
		  all
                  (VP benefited
                      (PP-CLR from
			      (NP (NP strong sales)
				  (PP of
				      (NP (NP (ADJP relatively new)
					      , 
					      higher-priced 
					      medicines)
					  (SBAR (WHNP-1 that)
						(S (NP-SBJ *T*-1)
						   (VP provide
						       (NP wide profit margins))))))))))))
     .))
( (S (NP-SBJ-1 (NP (ADJP Less robust)
		   earnings)
               (PP-LOC at
		       (NP (NP Pfizer Inc.)
			   and
			   (NP Upjohn Co.))))
     (VP were
         (VP attributed
             (NP *-1)
             (PP-CLR to
		     (NP (NP (NP those companies ')
			     older products)
			 ,
			 (SBAR (WHNP-2 (NP many) 
				       (WHPP of
					     (WHNP which)))
			       (S (NP-SBJ *T*-2)
				  (VP face
				      (NP (NP stiffening competition)
					  (PP from
					      (NP (NP generic drugs)
						  and
						  (NP other medicines)))))))))))
     .))
( (S (NP-SBJ (NP Joseph Riccardo)
             ,
             (NP (NP an analyst)
                 (PP with
                     (NP Bear , Stearns & Co.)))
             ,)
     (VP said
         (SBAR that
               (S (PP-TMP over
			  (NP the past few years))
                  (NP-SBJ-1 most drug makers)
                  (VP have
                      (VP (VP shed
                              (NP their slow-growing businesses))
                          and
                          (VP instituted
                              (NP (NP other cost savings)
                                  ,
                                  (PP such as
				      (S-NOM (NP-SBJ *-1)
					     (VP consolidating
						 (NP (NP manufacturing plants)
						     and
						     (NP administrative staffs))))))))))))
     .))
( (S (S-TPC-1 (PP-PRP As
		      (NP a result))
	      , 
	      ``
	      (NP-SBJ major new products)
	      (VP are
		  (VP having
		      (NP significant impact)
		      ,
		      (PP-CLR (ADVP even)
			      on
			      (NP (NP a company)
				  (PP with
				      (NP (ADJP very large)
					  revenues)))))))
     ,
     ''
     (NP-SBJ Mr. Riccardo)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S (NP-SBJ Analysts)
     (VP said
         (SBAR 0
               (S (NP-SBJ-1 (NP profit)
			    (PP for
				(NP (NP the 
					(QP dozen or so)
					big drug makers)
				    ,
				    (PP as
					(NP a group))
				    ,)))
                  (VP is
                      (VP estimated
                          (S (NP-SBJ *-1)
                             (VP to
                                 (VP have
                                     (VP climbed
                                         (NP-EXT (QP between 11 % and 14 %) *U*))))))))))
     .))
( (S (SBAR-ADV While
	       (S (NP-SBJ that)
		  (VP 's not
		      (ADJP-PRD spectacular))))
     ,
     (NP-SBJ (NP Neil Sweig)
             ,
             (NP (NP an analyst)
                 (PP with
                     (NP Prudential Bache)))
             ,)
     (VP said
         (SBAR that
               (S (NP-SBJ (NP the rate)
                          (PP of
                              (NP growth)))
                  (VP will
		      ``
                      (VP look
                          (ADJP-PRD especially good
                                    (SBAR as
                                          (S (NP-SBJ-1 *)
                                             (VP compared
						 (NP *-1)
                                                 (PP-CLR to
							 (NP other companies))))))
			  (SBAR-ADV if
				    (S (NP-SBJ the economy)
				       (VP turns
					   (ADVP-DIR downward)))))))))
     .
     ''))
( (S (NP-SBJ Mr. Sweig)
     (VP estimated
         (SBAR that
               (S (NP-SBJ-1 (NP (NP Merck 's)
				profit)
			    (PP for
				(NP the quarter)))
                  (VP rose
                      (PP-EXT by
			      (NP (QP about 22) %))
		      ,
		      (S-ADV (NP-SBJ-2 *-1)
			     (VP propelled
				 (NP *-2)
				 (PP by
				     (NP-LGS (NP sales)
					     (PP of
						 (NP (NP its line-up)
						     (PP of
							 (NP (NP fast-growing prescription drugs)
							     ,
							     (PP including
								 (NP (NP (NP its anti-cholesterol drug)
									 ,
									 (NP Mevacor))
								     ;
								     (NP (NP a high blood pressure medicine)
									 ,
									 (NP Vasotec))
								     ;
								     (NP (NP Primaxin)
									 ,
									 (NP an antibiotic))
								     , 
								     and
								     (NP (NP Pepcid)
									 ,
									 (NP an anti-ulcer medication))))))))))))))))
     .))
( (S (S-TPC-2 (NP-SBJ Profit)
	      (VP climbed
		  (SBAR-ADV even though
			    (S (NP-SBJ-1 (NP Merck 's)
					 sales)
			       (VP were
				   (VP reduced
				       (NP *-1)
				       (PP-EXT by
					       ``
					       (NP (QP one to three) percentage points)
					       '')
				       (PP-PRP as
					       (NP (NP a result)
						   (PP of
						       (NP the strong dollar))))))))))
     ,
     (NP-SBJ Mr. Sweig)
     (VP said
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (PP-TMP In
	     (NP (NP the third quarter)
		 (PP of
		     (NP 1988))))
     ,
     (NP-SBJ Merck)
     (VP earned
         (NP (NP (QP $ 311.8 million) *U*)
             ,
	     or
             (NP (NP 79 cents)
                 (NP-ADV a share))))
     .))
( (S (PP-LOC In
	     (NP (NP Rahway)
		 ,
		 (NP N.J.)
		 ,))
     (NP-SBJ a Merck spokesman)
     (VP said
         (SBAR 0
               (S (NP-SBJ the company)
                  (VP does n't
                      (VP make
                          (NP earnings projections))))))
     .))
( (S (NP-SBJ Mr. Sweig)
     (VP said
         (SBAR 0
               (S (NP-SBJ he)
                  (VP estimated
                      (SBAR that
                            (S (NP-SBJ (NP (NP Lilly 's)
					   earnings)
                                       (PP for
                                           (NP the quarter)))
                               (VP jumped
                                   (NP-EXT about 20 %)
                                   ,
				   (PP-PRP (ADVP largely)
					   because of
					   (NP (NP the performance)
					       (PP of
						   (NP its new anti-depressant
						       Prozac)))))))))))
     .))
( (S (NP-SBJ-1 (NP The drug)
	       ,
	       (VP introduced
		   (NP *) 
		   (NP-TMP last year))
	       ,)
     (VP is
         (VP expected
             (S (NP-SBJ *-1)
                (VP to
                    (VP generate
                        (NP (NP sales)
                            (PP of
                                (NP (QP about $ 300 million) *U*)))
			(NP-TMP this year))))))
     .))
( (S ``
     (S-TPC-1 (NP-SBJ-2 It)
	      (VP 's
		  (VP turning
		      (PRT out)
		      (S (NP-SBJ *-2)
			 (VP to
			     (VP be
				 (NP-PRD a real blockbuster)))))))
     ,
     ''
     (NP-SBJ Mr. Sweig)
     (VP said
	 (S *T*-1))
     .))
( (S (PP-TMP In
	     (NP (NP last year 's)
		 third quarter))
     ,
     (NP-SBJ Lilly)
     (VP earned
         (NP (NP (QP $ 171.4 million) *U*)
             , 
	     or
             (NP (NP $ 1.20 *U*)
                 (NP-ADV a share))))
     .))
( (S (PP-LOC In
	     (NP Indianapolis))
     ,
     (NP-SBJ Lilly)
     (VP declined
         (NP comment))
     .))
( (S (NP-SBJ Several analysts)
     (VP said
         (SBAR 0
               (S (NP-SBJ they)
                  (VP expected
		      (S (NP-SBJ (NP Warner-Lambert 's)
				 profit)
			 (ADVP also)
			 (VP to
                             (VP increase
                                 (PP-EXT by
					 (NP (QP more than 20) %))
				 (PP-DIR from
					 (NP (NP (NP (QP $ 87.7 million) *U*)
						 , 
						 or
						 (NP (NP $ 1.25 *U*)
						     (NP-ADV a share))
						 ,)
					     (SBAR (WHNP-2 0)
						   (S (NP-SBJ it)
						      (VP reported
							  (NP *T*-2)
							  (PP-TMP in
								  (NP (NP the like period)
								      (NP-TMP last year)))))))))))))))
     .))
( (S (NP-SBJ-1 The company)
     (VP is
         (VP praised
             (NP *-1)
             (PP by
                 (NP-LGS analysts))
             (PP-PRP for
		     (S-NOM (NP-SBJ *-1)
			    (VP (VP (ADVP-MNR sharply)
				    lowering
				    (NP its costs)
				    (PP-TMP in
					    (NP recent years)))
				and
				(VP shedding
				    (NP (NP numerous companies)
					(PP with
					    (NP low profit margins)))))))))
     .))
( (S-1 (NP-SBJ (NP The company 's)
	       lean operation)
       (PRN ,
	    (S (NP-SBJ analysts)
	       (VP said
		   (SBAR 0
			 (S *T*-1))))
	    ,)
       (VP allowed
	   (S (NP-SBJ (NP sharp-rising sales)
		      (PP from
			  (NP (NP its cholesterol drug)
			      ,
			      (NP Lopid)
			      ,)))
	      (VP to
		  (VP power
		      (NP earnings growth)))))
       .))
( (S (NP-SBJ-1 Lopid sales)
     (VP are
         (VP expected
             (S (NP-SBJ *-1)
                (VP to
                    (VP be
                        (NP-PRD (QP about $ 300 million) *U*)
			(NP-TMP this year)
			,
			(ADVP up
			      (PP from
				  (NP (QP $ 190 million) *U*)
				  (PP-TMP in
					  (NP 1988)))))))))
     .))
( (S (PP-LOC In
	     (NP (NP Morris Plains)
		 ,
		 (NP N.J.)
		 ,))
     (NP-SBJ (NP a spokesman)
             (PP for
                 (NP the company)))
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP the analysts ')
                          projections)
                  (VP are 
		      ``
		      (PP-LOC-PRD in
				  (NP the ballpark))))))
     .
     ''))
( (S (NP-SBJ-2 (NP Squibb 's)
	       profit)
     ,
     (S-ADV (NP-SBJ-3 *-2)
	    (VP estimated
		(PP by
		    (NP-LGS analysts))
		(S (NP-SBJ *-3)
		   (VP to
		       (VP be
			   (PP-LOC-PRD (NP (QP about 18) %)
				       above
				       (NP (NP (NP the (QP $ 123 million) *U*)
					       , 
					       or
					       (NP (NP $ 1.25 *U*)
						   (NP-ADV a share)))
					   ,
					   (SBAR (WHNP-1 0)
						 (S (NP-SBJ it)
						    (VP earned
							(NP *T*-1)
							(PP-TMP in
								(NP (NP the third quarter)
								    (PP of
									(NP 1988)))))))
					   ,)))))))
     (VP was
         (NP-PRD (NP the result)
                 (PP of
                     (NP (NP (ADJP especially strong)
			     sales)
                         (PP of
                             (NP (NP its Capoten drug)
                                 (PP for
                                     (S-NOM (NP-SBJ *)
					    (VP treating
						(NP (NP high blood pressure)
						    and
						    (NP other heart disease)))))))))))
     .))
( (S (NP-SBJ-1 The company)
     (VP was
	 (VP (ADVP-MNR officially)
	     merged
             (NP *-1)
             (PP-CLR with
		     (NP Bristol-Myers Co.))
	     (NP-TMP earlier this month)))
     .))
( (S (NP-SBJ-1 Bristol-Myers)
     (VP declined
         (S (NP-SBJ *-1)
            (VP to
                (VP comment))))
     .))
( (S (NP-SBJ (NP Mr. Riccardo)
             (PP of
                 (NP Bear Stearns)))
     (VP said
         (SBAR that
               (S (NP-SBJ (NP (NP (NP Schering-Plough Corp. 's)
				  expected profit rise)
                              (PP of
                                  (NP (QP about 18 % to 20 %) *U*)))
                          , 
			  and
                          (NP (NP (NP Bristol-Meyers 's)
				  expected profit increase)
                              (PP of
				  (NP (QP about 13) %))))
                  (VP are
		      (SBAR-PRP-PRD (ADVP largely)
				    because
				    ``
				    (S (NP-SBJ-1 those companies)
				       (VP are
					   (ADVP really)
					   (VP managed
					       (NP *-1)
					       (ADVP-MNR well)))))))))
     .
     ''))
( (S (NP-SBJ ScheringPlough)
     (VP earned
         (NP (NP (QP $ 94.4 million) *U*)
             , 
	     or
             (NP (NP 84 cents)
                 (NP-ADV a share)))
	 ,
	 (SBAR-ADV while
		   (S (NP-SBJ Bristol-Myers)
		      (VP earned
			  (NP (NP (QP $ 232.3 million) *U*)
			      ,
			      or
			      (NP (NP 81 cents)
				  (NP-ADV a share)))
			  ,
			  (PP-TMP in
				  (NP (NP the like period)
				      (ADVP-TMP (NP a year)
						earlier)))))))
     .))
( (S (PP-LOC In
	     (NP (NP Madison)
		 ,
		 (NP N.J.)))
     ,
     (NP-SBJ (NP a spokesman)
             (PP for
                 (NP Schering-Plough)))
     (VP said
         (SBAR 0
               (S (NP-SBJ the company)
                  (VP has
                      (NP `` 
			  (NP no problems)
			  ''
                          (PP with
                              (NP (NP the average estimate
				      (SBAR *ICH*-1))
                                  (PP by
                                      (NP a analysts))
                                  (SBAR-1 that
					  (S (NP-SBJ (NP third-quarter earnings)
						     (PP per
							 (NP share)))
					     (VP rose
						 (PP-EXT by
							 (NP (QP about 19) %))
						 ,
						 (PP-DIR to
							 (NP $ 1 *U*))))))))))))
     .))
( (S (S-TPC-2 (NP-SBJ-1 The company)
	      (VP expects
		  (S (NP-SBJ *-1)
		     (VP to
			 (VP achieve
			     (NP (NP the
				     (ADJP 20 %)
				     increase)
				 (PP-LOC in
					 (NP full-year earnings))
				 (PP per
				     (NP share)))
			     ,
			     (SBAR-ADV as
				       (S (NP-SBJ it)
					  (VP projected
					      (PP in
						  (NP the spring))))))))))
     ,
     (NP-SBJ the spokesman)
     (VP said
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (ADVP-TMP Meanwhile)
     ,
     (NP-SBJ analysts)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP (NP Pfizer 's)
			      recent string)
                          (PP of
                              (NP lackluster quarterly performances)))
                  (VP continued
		      ,
		      (SBAR-ADV as
				(S (NP-SBJ-1 (NP earnings)
					     (PP-TMP in
						     (NP the quarter)))
				   (VP were
				       (VP expected
					   (S (NP-SBJ *-1)
					      (VP to
						  (VP decline
						      (PP-EXT by
							      (NP (QP about 5) %)))))))))))))
     .))
( (S (NP-SBJ (NP Sales)
             (PP of
                 (NP (NP (NP Pfizer 's)
                         important drugs)
                     ,
                     (NP (NP (NP Feldene)
			     (PP for
				 (S-NOM (NP-SBJ *)
					(VP treating
					    (NP arthritis)))))
                         , 
			 and
                         (NP (NP Procardia)
                             ,
                             (NP a heart medicine)
                             ,)))))
     (VP have
         (VP shrunk
	     (PP-PRP because of
		     (NP increased competition))))
     .))
( (S ``
     (S-TPC-1 (NP-SBJ The 
		      (PRN -LRB- 
			   strong 
			   -RRB-)
		      dollar)
	      (VP hurt
		  (NP Pfizer)
		  (NP-ADV a lot)
		  ,
		  (ADVP too)))
     , 
     ''
     (NP-SBJ Mr. Sweig)
     (VP said
	 (S *T*-1))
     .))
( (S (PP-TMP In
	     (NP the third quarter))
     (NP-TMP last year)
     ,
     (NP-SBJ Pfizer)
     (VP earned
         (NP (NP (QP $ 216.8 million) *U*)
             , 
	     or
             (NP (NP $ 1.29 *U*)
                 (NP-ADV a share))))
     .))
( (S (PP-LOC In
	     (NP New York))
     ,
     (NP-SBJ the company)
     (VP declined
         (NP comment))
     .))
( (S (NP-SBJ Analysts)
     (VP said
         (SBAR 0
               (S (NP-SBJ they)
                  (VP expected
		      (S (NP-SBJ (NP Upjohn 's)
				 profit)
                         (VP to
                             (VP (VP be
                                     (ADJP-PRD flat))
                                 or
                                 (VP rise
                                     (PP-EXT by
					     (NP (NP (QP only about 2 % to 4 %) *U*)
						 (SBAR as
						       (S (NP-SBJ-2 *)
							  (VP compared
							      (NP *-2)
							      (PP-CLR with
								      (NP (NP (NP (QP $ 89.6 million) *U*)
									      , 
									      or
									      (NP (NP 49 cents)
										  (NP-ADV a share)))
									  ,
									  (SBAR (WHNP-1 0)
										(S (NP-SBJ it)
										   (VP earned
										       (NP *T*-1)
										       (ADVP-TMP (NP a year)
												 ago)))))))))))))))))))
     .))
( (S (NP-SBJ (NP Upjohn 's)
             biggest-selling drugs)
     (VP are
         (NP-PRD (NP (NP Xanax)
                     ,
                     (NP a tranquilizer))
                 , 
		 and
                 (NP (NP Halcion)
                     ,
                     (NP a sedative))))
     .))
( (S (NP-SBJ-1 (NP Sales)
               (PP of
                   (NP both drugs)))
     (VP have
         (VP been
             (VP hurt
                 (NP *-1)
                 (PP by
                     (NP-LGS (NP (NP new state laws)
				 (VP restricting
				     (NP (NP the prescriptions)
					 (PP of
					     (NP certain tranquilizing medicines)))))
			     and
			     (NP (NP adverse publicity)
				 (PP about
				     (NP (NP the excessive use)
					 (PP of
					     (NP the drugs))))))))))
     .))
( (S (S-TPC-2 (ADVP Also)
	      ,
	      (S (NP-SBJ (NP (NP the company 's)
			     hair-growing drug)
			 ,
			 (NP Rogaine)
			 ,)
		 (VP is
		     (VP selling
			 (ADVP-MNR well)
			 --
			 (PP at
			     (NP (NP (QP about $ 125 million) *U*)
				 (PP for
				     (NP the year)))))))
	      , 
	      but
	      (S (NP-SBJ-1 (NP (NP the company 's)
			       profit)
			   (PP from
			       (NP the drug)))
		 (VP has
		     (VP been
			 (VP reduced
			     (NP *-1)
			     (PP by
				 (NP-LGS (NP (NP Upjohn 's)
					     expensive print and television campaigns)
					 (PP for
					     (NP advertising)))))))))
     ,
     (NP-SBJ analysts)
     (VP said
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (PP-LOC In
	     (NP (NP Kalamazoo)
		 ,
		 (NP Mich.)
		 ,))
     (NP-SBJ Upjohn)
     (VP declined
         (NP comment))
     .))
